Not to be used for dementia-related psychosis &/or behavioural disturbances or treatment of dopamine agonist associated psychosis in Parkinson's. Discontinue if patient developed signs & symptoms of neuroleptic malignant syndrome (NMS) or presents w/ unexplained high fever w/o additional clinical manifestations of NMS; in cases of hepatitis; acute symptoms (eg, sweating, insomnia, tremor, anxiety, nausea or vomiting). Observe for signs & symptoms of hyperglycaemia. Monitor regularly for worsening of glucose control in patients w/ or w/ risk factors for DM, weight (eg, at baseline, 4, 8 & 12 wk after starting treatment & quarterly thereafter), lipids (eg, at baseline, 12 wk after starting treatment & every 5 yr thereafter). Patients w/ prostatic hypertrophy, or paralytic ileus & related conditions; elevated ALT &/or AST, signs & symptoms of hepatic impairment, preexisting conditions associated w/ limited hepatic functional reserve & those treated w/ potentially hepatotoxic drugs; patients w/ low leukocyte &/or neutrophil counts, & in those receiving drugs known to cause neutropenia, history of drug-induced bone marrow depression/toxicity, & in those w/ bone marrow depression caused by concomitant illness, radiation or chemotherapy, hypereosinophilic conditions or w/ myeloproliferative disease, concomitant use w/ valproate; coadministration w/ drugs known to increase QTc interval (especially in elderly), patients w/ congenital long QT syndrome, CHF, heart hypertrophy, hypokalaemia or hypomagnesaemia; coadministration w/ other centrally acting drugs & alcohol; history of seizures, or are subject to factors which may lower seizure threshold. Venous thromboembolism. Discontinue or reduce dose if tardive dyskinesia occurs. Measure BP periodically for patients >65 yr. Sudden cardiac death. Zyprexa contains lactose; not to be taken in patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Zyprexa Zydis contains aspartame (harmful for people w/ phenylketonuria), mannitol, Na methyl parahydroxybenzoate & Na propyl parahydroxybenzoate (known to cause urticaria). May affect ability to drive or operate machinery. Pregnancy & lactation. Childn & adolescent <18 yr.